APA

Sun J., Xie Q., Tan D., Ning Q., Niu J., Bai X., Fan R., Chen S., Cheng J., Yu Y., Wang H., Xu M., Shi G., Wan M., Chen X., Tang H., Sheng J., Dou X., Shi J., Ren H., Wang M., Zhang H., Gao Z., Chen C., Ma H., Jia J. & Hou J. (20140609). The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. : Hepatology (Baltimore, Md.).

Chicago

Sun Jian, Xie Qing, Tan Deming, Ning Qin, Niu Junqi, Bai Xuefan, Fan Rong, Chen Shijun, Cheng Jun, Yu Yanyan, Wang Hao, Xu Min, Shi Guangfeng, Wan Mobin, Chen Xinyue, Tang Hong, Sheng Jifang, Dou Xiaoguang, Shi Junping, Ren Hong, Wang Maorong, Zhang Hongfei, Gao Zhiliang, Chen Chengwei, Ma Hong, Jia Jidong and Hou Jinlin. 20140609. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. : Hepatology (Baltimore, Md.).

Harvard

Sun J., Xie Q., Tan D., Ning Q., Niu J., Bai X., Fan R., Chen S., Cheng J., Yu Y., Wang H., Xu M., Shi G., Wan M., Chen X., Tang H., Sheng J., Dou X., Shi J., Ren H., Wang M., Zhang H., Gao Z., Chen C., Ma H., Jia J. and Hou J. (20140609). The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. : Hepatology (Baltimore, Md.).

MLA

Sun Jian, Xie Qing, Tan Deming, Ning Qin, Niu Junqi, Bai Xuefan, Fan Rong, Chen Shijun, Cheng Jun, Yu Yanyan, Wang Hao, Xu Min, Shi Guangfeng, Wan Mobin, Chen Xinyue, Tang Hong, Sheng Jifang, Dou Xiaoguang, Shi Junping, Ren Hong, Wang Maorong, Zhang Hongfei, Gao Zhiliang, Chen Chengwei, Ma Hong, Jia Jidong and Hou Jinlin. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. : Hepatology (Baltimore, Md.). 20140609.